Kidney Cancer
Renal cell carcinoma may be treated by the small molecule inhibitor SU11248
Published in Cancer Weekly, March 14th, 2006
According to a study from the United States, "RCC is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC."
"Patients with metastatic RCC and progression on first-line cytokine therapy were enrolled onto a multicenter phase II...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-03-14)
More Articles from Cancer Weekly
- Clinical Trials
Strategy to recruit Asian Americans for cancer clinical trials discussed - Melanoma
Integrin alphavbeta3 and cofilin modulate K1735 melanoma cell invasion - Pancreatic Cancer
p8 proposed as new target of gemcitabine in pancreatic cancer cells - Prostate Cancer
P1NP used to predict metastases, progression, and survival in prostate cancer - Adverse Drug Reaction
Osteonecrosis of the jaw related to pamidronate therapy - Antibiotics
Antibiotic use and survival in advanced cancer patients with infections examined - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
